Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Imeglimin in Moderate Hepatic Impairment
NCT03802786Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Poxel SA. Primary endpoint: Pharmacokinetic parameters of imeglimin at Day 1. Started Nov 2018; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03802786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802786.